Article Text

Download PDFPDF
General medicine
Lorcaserin in obesity: minimal benefits and ill-defined harms

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors IJO and JKA both contributed equally to the text.

  • Competing interests IJO and JKA are coauthors of a previously published systematic review and meta-analysis that assessed the benefits and harms of centrally acting antiobesity medicines. IJO holds grant funding from the NIHR School of Primary Care Research (NIHR Evidence Synthesis working group Project No 390).

  • Patient consent Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.